Nature论文发现Wee1抑制剂毒性新机制,或指引更安全用药
The hidden role of a cancer treatment target could explain toxic side effects
一项发表在Nature的研究揭示,Wee1在细胞周期早期帮助关闭蛋白降解复合物以促进DNA复制;抑制Wee1可能阻滞肠道和血液等正常快速增殖细胞的复制,从而产生毒性副作用。研究团队据此提出,蛋白质降解复合物活性降低的肿瘤可能对Wee1抑制剂更敏感,提示可通过选择性抑制或剂量调整来改善治疗窗口。
Wee1 inhibitors are a promising new cancer treatment, but serious side effects threaten their adoption in the clinic. Now, researchers from the MRC Laboratory of Medical Sciences (LMS), the University of Oxford and UCL have discovered a previously unknown role for Wee1 that could explain these effects.
The findings could realign the drugs' clinical progress, helping to identify patients most likely to benefit from treatment and guiding the development of safer, more targeted therapies.
Toxic side effects are derailing a promising group of clinical trials using Wee1 inhibitors in cancer patients. A study published in Nature, resulting from an interdisciplinary combination of mathematical modeling and lab experiments, might explain these wayward effects and point the way to improving outcomes or better identification of patient populations who could benefit the most.
Cells have several safeguards to stop DNA damage leading to cancer. One of the most important is the tumor-suppressor protein p53, which can halt the cell cycle when DNA damage is detected. However, p53 is inactive in around half of all cancers, allowing damaged cells to continue growing.
Wee1 forms part of a second line of defense, acting as a backup brake that prevents DNA-damaged cells from entering cell division. Because p53-mutated cancers rely on this remaining safeguard, Wee1 has become a promising drug target.
Researchers have now shown that, in addition to this established role, Wee1 also has a previously unappreciated role earlier in the cell cycle in healthy cells.
"Wee1 has been very intensely studied in the later stages of the cell cycle, where targeting its activity for cancer treatment makes sense," says Alexis, head of the Cell Cycle Control group at the LMS.
"However, the side effects of Wee1 inhibitors in patients were hard to explain based on these functions, so we started to wonder if this Wee1 enzyme had some other function that we hadn't appreciated that could explain these. We wanted to look earlier in the cell cycle to see if there was something we had missed."
Taking action early
The team set out to interrogate the established understanding of Wee1's role in early cell cycle stages by constructing a mathematical model that predicts the impact of inhibiting Wee1. But when the team tested the model's predictions in healthy and cancerous cells, it became clear that the image of Wee1's activity as painted by the scientific literature was wrong.
Alexis says, "We quickly found out that the model we had based on the literature on Wee1 was wrong because that was not what we saw in cells. What had been missed was an early function of Wee1 that people hadn't looked at."
In healthy cells, a protein degradation complex prevents DNA replication from starting by breaking down molecules needed for the process. Wee1 helps switch off this complex early in the cell cycle, allowing DNA replication to begin. Without Wee1, the protein degradation complex remains active, delaying or preventing cells from progressing through the cell cycle.
"We think what's happening in patients is that when they're being treated with these Wee1 inhibitors, it's stopping their normal fast-proliferating cells, like you get in the colon and the blood system, from starting to replicate," says Alexis. "And so those cells are stuck, unable to generate new cells, and that could be causing some of the toxic side effects."
More effective treatment for those who might benefit the most
If the side effects are linked to Wee1's role in the protein degradation complex, the researchers suggest that cancers with reduced activity of this complex may be particularly susceptible to Wee1 inhibitors. This could create a therapeutic window in which lower doses of the treatment could kill cancer cells while minimizing damage to healthy cells and reducing side effects.
Another approach could be to target Wee1 more selectively. "We're also starting to think about if there are different ways we could inhibit Wee1 that get around this early cell cycle function," says Alexis, "though how this might be achieved is a work in progress."
Refining clinical trials, improving cancer treatments
It was a surprise to discover such a fundamental role of a drug target that has been so thoroughly interrogated en route to clinical trial. "Now we've uncovered this new function for Wee1, are there other functions that we haven't appreciated? What else is it doing that we have not seen since we've not looked at the right stage?" asks Alexis.
Another pressing goal is to further test the predictions of this work in preclinical models and in patients currently enrolled in Wee1 inhibitor clinical trials. Bringing this new understanding into ongoing clinical trials could transform the prospects for Wee1 inhibitors, helping to overcome the side effects threatening their development and offering new hope to patients.
This work was part of a collaboration between the LMS, Hiro Yamano at UCL and the late Béla Novák of the University of Oxford.
Publication details
Alexis Barr, WEE1 opposes APC/CCDH1 activity to promote S phase entry, Nature (2026). DOI: 10.1038/s41586-026-11188-x. www.nature.com/articles/s41586-026-11188-x
Journal information: Nature
Key medical concepts
Who's behind this story?
Sadie Harley
BSc Life Sciences & Ecology. Microbiology lab background with pharmaceutical news experience in oil, gas, and renewable industries. Full profile →
Robert Egan
Bachelor's in mathematical biology, Master's in creative writing. Well-traveled with unique perspectives on science and language. Full profile →
Citation: The hidden role of a cancer treatment target could explain toxic side effects (2026, October 21) retrieved 21 October 2026 from https://medicalxpress.com/news/2026-10-hidden-role-cancer-treatment-toxic.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
来源:Medical Xpress · medicalxpress.com